Last reviewed · How we verify
Triple negative breast neoplasms
Approved treatments
- Pembrolizuma · Memorial Sloan Kettering Cancer Center
- Trodelvy · Immunomedics Inc
Trodelvy works by binding to the TACI receptor on cancer cells, triggering a cascade of events that ultimately leads to cell death.
Clinical guidelines
- FDA label — 3L+
TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. - FDA label — 3L+
TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Triple negative breast neoplasms patent landscape — cliff calendar, originator estates, attackable patents
- Triple negative breast neoplasms treatment landscape brief
- Triple negative breast neoplasms treatment updates RSS
Frequently asked questions about Triple negative breast neoplasms
What drugs treat Triple negative breast neoplasms?
Tracked treatments include Pembrolizuma, Trodelvy.
What is the treatment for Triple negative breast neoplasms?
Standard treatment for Triple negative breast neoplasms includes Pembrolizuma, Trodelvy. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Triple negative breast neoplasms?
FDA label publishes guidelines for Triple negative breast neoplasms. 2 guideline references tracked.
Related
- Treatment landscape: Triple negative breast neoplasms patent cliff · Triple negative breast neoplasms CI report
- Treatment: Pembrolizuma · Memorial Sloan Kettering Cancer Center
- Treatment: Trodelvy · Immunomedics Inc
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing